Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
Clinical trial NCT06095583 · RECRUITING
Trial details
- NCT number
- NCT06095583
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-15
- Primary completion
- 2027-07-31
- Enrollment
- 756
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.